ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
ALX Oncology (Nasdaq: ALXO) will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ALX Oncology (Nasdaq: ALXO) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Jason Lettmann and Chief Medical Officer Barbara Klencke will deliver a corporate presentation and fireside chat on January 15, 2026 at 12:00 p.m. PT. A live webcast will be available via the Investors section of ALX Oncology’s website under Events and Presentations. A replay of the webcast will be archived and available for up to 90 days after the fireside chat.
Details
News Market Reaction – ALXO
On Jan 8, the day this news came out, ALXO closed 5.08% above the previous close.
Data tracked by StockTitan Argus for the Jan 8 session.
Key Figures
- Conference edition
- 44th
- 44th Annual J.P. Morgan Healthcare Conference
- Presentation date
- January 15, 2026
- Corporate presentation at J.P. Morgan Healthcare Conference
- Presentation time
- 12:00 p.m. Pacific Time
- Scheduled time for corporate presentation
- Webcast archive duration
- 90 days
- Replay of webcast available after fireside chat
- Current price
- $1.18
- Pre-news market price for ALXO
- Daily change
- 9.26%
- Price change over prior 24 hours
- 52-week high
- $2.27
- 52-week trading range high
- 52-week low
- $0.404
- 52-week trading range low
Historical Context
-
Positive Phase 2 lymphoma data for evorpacept with strong response rates.
-
Announcement of participation in Jefferies and Piper Sandler healthcare conferences.
-
Q3 2025 results, strong ASPEN‑06 biomarker analysis, and cash runway into Q1 2027.
-
Upcoming Q3 results and SITC biomarker data preview for evorpacept.
-
Preclinical and Phase 1 design data for EGFR‑targeted ADC ALX2004 at oncology meeting.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Jason Lettmann and Chief Medical Officer Barbara Klencke will deliver a corporate presentation on Thursday, January 15, 2026, at 12:00 p.m. Pacific Time.
The live webcast of the J.P. Morgan fireside chat can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com under the Events section of the Events and Presentations tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Michele Parisi, SparkPoint Healthcare Communications
mparisi@sparkpointpr.com
(925) 864-5028
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.